Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Expert Opin Biol Ther. 2021 May 9;22(8):1017–1027. doi: 10.1080/14712598.2021.1922665

Figure 2:

Figure 2:

Various bispecific antibody formats are shown as whole antibody molecules or engineered antibody derivatives containing variable regions of heavy and light chains. The heavy chains targeting CD3 and TAA are depicted in dark blue and red respectively. The light chains targeting CD3 and TAA are depicted in light blue and pink, respectively BiTE = Bispecific T cell engager; Chemical heteroconjugate = two antibodies linked; DART= Dual-affinity retargeting bispecific antibody; Trifunctional Antibody: quadroma fusion with Fc-binding portion; TanB; bispecific tetravalent chimeric antibody construct; BIKE: Bispecific killer cell engagers; Diabody: basic construct of genetically fusing variable domains of the heavy and light chains with linkers. The heavy chains targeting CD3 and TAA are depicted in dark blue and red respectively. The light chains targeting CD3 and TAA are depicted in light blue and pink, respectively.